Design and synthesis of novel 6,7-imidazotetrahydroquinoline inhibitors of thymidylate synthase using iterative protein crystal structure analysisREICH, S. H; FUHRY, M. A. M; BARTLETT, C. A et al.Journal of medicinal chemistry (Print). 1992, Vol 35, Num 5, pp 847-858, issn 0022-2623Article

An antibody-catalyzed Claisen rearrangementJACKSON, D. Y; JACOBS, J. W; SUGASAWARA, R et al.Journal of the American Chemical Society. 1988, Vol 110, Num 14, pp 4841-4842, issn 0002-7863Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 2. Peptide structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; TIKHE, J et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2819-2834, issn 0022-2623Article

Bis tertiary amide inhibitors of the HIV-1 protease generated via protein structure-based iterative designMELNICK, M; REICH, S. H; MUSICK, L et al.Journal of medicinal chemistry (Print). 1996, Vol 39, Num 14, pp 2795-2811, issn 0022-2623Article

Chorismate mutase inhibitors: synthesis and evaluation of some potential transition-state analoguesBARTLETT, P. A; NAKAGAWA, Y; JOHNSON, C. R et al.Journal of organic chemistry. 1988, Vol 53, Num 14, pp 3195-3210, issn 0022-3263Article

Viracept (nelfinavir mesylate, AG1343) : A potent, orally bioavailable inhibitor of HIV-1 proteaseKALDOR, S. W; KALISH, V. J; DRESSMAN, B. A et al.Journal of medicinal chemistry (Print). 1997, Vol 40, Num 24, pp 3979-3985, issn 0022-2623Article

Structure-based design and synthesis of substituted 2-butanols as nonpeptidic inhibitors of HIV protease : Secondary amide seriesREICH, S. H; MELNICK, M; PINO, M. J et al.Journal of medicinal chemistry (Print). 1996, Vol 39, Num 14, pp 2781-2794, issn 0022-2623Article

Design of enzyme inhibitors using iterative protein crystallographic analysisAPPELT, K; BACQUET, R. J; JONES, T. R et al.Journal of medicinal chemistry (Print). 1991, Vol 34, Num 7, pp 1925-1934, issn 0022-2623Article

Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 1. Michael acceptor structure-activity studiesDRAGOVICH, P. S; WEBBER, S. E; LITTLEFIELD, E. S et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2806-2818, issn 0022-2623Article

Tripeptide aldehyde inhibitors of human rhinovirus 3C protease : Design, synthesis, biological evaluation, and cocrystal structure solution of P₁ glutamine isosteric replacementsWEBBER, S. E; OKANO, K; MEADOR, J. W et al.Journal of medicinal chemistry (Print). 1998, Vol 41, Num 15, pp 2786-2805, issn 0022-2623Article

Enantioselective total synthesis of 9S-dihydroerythronolide A seco acidCHAMBERLIN, A. R; DEZUBE, M; REICH, S. H et al.Journal of the American Chemical Society. 1989, Vol 111, Num 16, pp 6247-6256, issn 0002-7863, 10 p.Article

Stereoselective acyclic enolate formation via conjugate reduction: correlation with enone conformational preferencesCHAMBERLIN, A. R; REICH, S. H.Journal of the American Chemical Society. 1985, Vol 107, Num 5, pp 1440-1441, issn 0002-7863Article